FAMILIAL CHYLOMICRONEMIA SYNDROME
Clinical trials for FAMILIAL CHYLOMICRONEMIA SYNDROME explained in plain language.
Never miss a new study
Get alerted when new FAMILIAL CHYLOMICRONEMIA SYNDROME trials appear
Sign up with your email to follow new studies for FAMILIAL CHYLOMICRONEMIA SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug offers hope for rare fat disorder patients
Disease control OngoingThis study tests the safety of a new drug, olezarsen, in 24 adults with familial chylomicronemia syndrome (FCS), a rare condition causing extremely high blood fats. Participants had previously taken volanesorsen. The study monitors side effects like low platelet counts and kidney…
Matched conditions: FAMILIAL CHYLOMICRONEMIA SYNDROME
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New drug shows promise in controlling rare fat disorder
Disease control OngoingThis study looks at how well the drug olezarsen works over time to lower fat levels in the blood of people with familial chylomicronemia syndrome (FCS), a rare genetic condition. About 60 participants who completed a prior study will receive the drug for up to 3 years. The main g…
Matched conditions: FAMILIAL CHYLOMICRONEMIA SYNDROME
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 18, 2026 12:10 UTC
-
New shot aims to tame dangerous fat levels in blood
Disease control OngoingThis study tests a new medicine called RN0361 in healthy adults and people with very high triglycerides (a type of fat in the blood). The goal is to see if a single dose is safe and can lower fat levels. About 108 participants will receive either the drug or a placebo. The study …
Matched conditions: FAMILIAL CHYLOMICRONEMIA SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: Ikaria Bioscience Pty Ltd • Aim: Disease control
Last updated May 15, 2026 11:53 UTC